Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus
NCT01188863
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG:
300 mg LX4211 (150 mg tablets)
DRUG:
300 mg LX4211 (50 mg tablets)
DRUG:
300 mg LX4211 (liquid)
Sponsor
Lexicon Pharmaceuticals